Bain Capital

Schizophrenia-minded Syremis takes off with $165M series A

Founded by a team of neuropsychiatric-focused Teva alums and the force behind Cobenfy maker Karuna, Syremis touts a M1/M4 agonist and other prospects.

Zoey Becker Dec 18, 2025 12:59pm

Kailera raises hefty $600M to take Zepbound rival into ph. 3

Oct 14, 2025 9:20am

Graphic image of an arrow nailing the bullseye of a target

Areteia posts ph. 3 asthma win for oral rival to biologic drugs

Sep 16, 2025 9:20am

Apreo Health nets $130M to develop lung scaffold for emphysema

Aug 8, 2025 11:30am

christmas cash gift money present holiday

BMS hands 5 autoimmune drugs to Bain-backed spinout

Jul 29, 2025 5:08am

Business person contemplating how to navigate a maze made of money

Third Rock-backed Merida unveils with $121M for autoimmune plans

Apr 8, 2025 11:03am